Literature DB >> 15119976

The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples.

B Y Sarfo1, S Singh, J W Lillard, A Quarshie, R K Gyasi, H Armah, A A Adjei, P Jolly, J K Stiles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15119976     DOI： 10.1179/000349804225003271

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN： 0003-4983


× No keyword cloud information.
  24 in total

Review 1.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

2.  Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria.

Authors:  Daniel O Ochiel; Gordon A Awandare; Christopher C Keller; James B Hittner; Peter G Kremsner; J Brice Weinberg; Douglas J Perkins
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria.

Authors:  Gabriele S V Campanella; Andrew M Tager; Joseph K El Khoury; Seddon Y Thomas; Tabitha A Abrazinski; Lindsay A Manice; Richard A Colvin; Andrew D Luster
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-17       Impact factor: 11.205

4.  Plasmodium falciparum-infected erythrocytes induce NF-kappaB regulated inflammatory pathways in human cerebral endothelium.

Authors:  Abhai K Tripathi; Wei Sha; Vladimir Shulaev; Monique F Stins; David J Sullivan
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

5.  Cerebral malaria in children is associated with long-term cognitive impairment.

Authors:  Chandy C John; Paul Bangirana; Justus Byarugaba; Robert O Opoka; Richard Idro; Anne M Jurek; Baolin Wu; Michael J Boivin
Journal:  Pediatrics       Date:  2008-06-09       Impact factor: 7.124

6.  Host biomarkers and biological pathways that are associated with the expression of experimental cerebral malaria in mice.

Authors:  Miranda S Oakley; Thomas F McCutchan; Vivek Anantharaman; Jerrold M Ward; Laurence Faucette; Cindy Erexson; Babita Mahajan; Hong Zheng; Victoria Majam; L Aravind; Sanjai Kumar
Journal:  Infect Immun       Date:  2008-07-21       Impact factor: 3.441

7.  Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria.

Authors:  Chandy C John; Angela Panoskaltsis-Mortari; Robert O Opoka; Gregory S Park; Paul J Orchard; Anne M Jurek; Richard Idro; Justus Byarugaba; Michael J Boivin
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

8.  Glucocorticosteroids in nano-sterically stabilized liposomes are efficacious for elimination of the acute symptoms of experimental cerebral malaria.

Authors:  Judith H Waknine-Grinberg; Simcha Even-Chen; Jasmine Avichzer; Keren Turjeman; Annael Bentura-Marciano; Richard K Haynes; Lola Weiss; Nahum Allon; Haim Ovadia; Jacob Golenser; Yechezkel Barenholz
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

9.  Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.

Authors:  Nana O Wilson; Wesley Solomon; Leonard Anderson; John Patrickson; Sidney Pitts; Vincent Bond; Mingli Liu; Jonathan K Stiles
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Angiotensin II is a new component involved in splenic T lymphocyte responses during Plasmodium berghei ANKA infection.

Authors:  João Luiz Silva-Filho; Mariana Conceição Souza; Claudio Teixeira Ferreira-Dasilva; Leandro Souza Silva; Maria Fernanda Souza Costa; Tatiana Almeida Padua; Maria das Graças Henriques; Alexandre Morrot; Wilson Savino; Celso Caruso-Neves; Ana Acacia Sá Pinheiro
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.